News
Latest valve and structural heart intelligence
Filter by Source
Filter by Tag
Abbott kicks off new research on software-guided, balloon-expandable TAVR system
Abbott has initiated new research on a software-guided, balloon-expandable transcatheter aortic valve replacement system. No specific clinical data or trial endpoints were provided in the article content.
Digest: Abbott's entry into balloon-expandable TAVR with software guidance could challenge Edwards and Medtronic's market dominance and potentially improve procedural precision and outcomes.
TAVR just as safe when performed by early-career operators
A study demonstrates that transcatheter aortic valve replacement procedures performed by early-career operators achieve safety outcomes comparable to those of experienced operators. This finding supports the broader adoption of TAVR technology and operator training programs.
Digest: This evidence may inform hospital credentialing decisions and training pathways for TAVR programs, potentially expanding procedural access as volumes continue to grow across risk categories.

Device shows benefit in severe tricuspid regurgitation
The CLASP II TR trial randomized 450 patients with symptomatic severe tricuspid regurgitation to transcatheter tricuspid valve repair with the Pascal Precision system (Edwards Lifesciences) versus optimal medical therapy alone. At 1 year, the device improved health status and reduced TR severity compared with medical therapy, though no significant difference was observed in mortality or heart failure hospitalization.
Digest: This represents the first randomized controlled trial data for the FDA-approved Pascal Precision system in tricuspid regurgitation, providing evidence for transcatheter intervention in a valve position historically undertreated and associated with poor outcomes.
Heart surgery outperforms TAVR in new 5-year study of young, low-risk patients
A new 5-year study demonstrates superior outcomes for surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with aortic stenosis. The longer-term follow-up data suggest SAVR maintains advantages over TAVR in this specific patient population.
Digest: These findings may influence treatment algorithms and guideline recommendations for younger, low-risk aortic stenosis patients where long-term durability and optimal outcomes are critical considerations.
Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS
Medtronic has initiated a clinical study evaluating the safety and effectiveness of its self-expanding transcatheter aortic valve replacement (TAVR) systems in patients with moderate aortic stenosis. The trial represents an expansion into earlier-stage disease beyond current severe symptomatic AS indications.
Digest: This trial could potentially expand TAVR treatment paradigm to moderate AS patients, representing a significant market opportunity and earlier intervention strategy that would shift current guidelines recommending watchful waiting.
Abbott Begins Enrollment in Global Trial of Investigational Mitral Valve Replacement System
Abbott has initiated enrollment in a global clinical trial evaluating its investigational transcatheter mitral valve replacement system. No specific enrollment targets, trial design details, or timeline information were provided in the article.
Digest: This represents Abbott's strategic entry into the competitive TMVR market, currently dominated by early-stage investigational devices from Edwards and Medtronic.
Elucid Presents Data from ELUCIDATE Study at TCT
Elucid presented data from the ELUCIDATE study at the Transcatheter Cardiovascular Therapeutics (TCT) conference. Specific clinical findings and outcomes from the study were not detailed in the available content.
Digest: ELUCIDATE study findings may provide insights into advanced imaging or plaque characterization technologies relevant to risk stratification in structural heart disease patients.
Medtronic Presents Design and Baseline Characteristics of Patients in the Evolut EXPAND TAVR II Trial
Medtronic presented the trial design and baseline patient characteristics from the Evolut EXPAND TAVR II trial. The presentation provides foundational data on the patient population enrolled in this ongoing clinical investigation of the Evolut transcatheter aortic valve platform.
Digest: Understanding baseline characteristics and trial design is essential for interpreting future outcomes data and assessing the applicability of results to real-world TAVR populations.
New stroke prevention device for TAVR falls short, raising questions about the value of embolic protection
A new embolic protection device designed to prevent stroke during TAVR procedures failed to meet its clinical endpoints. The negative results call into question the overall clinical value and efficacy of embolic protection strategies in transcatheter aortic valve replacement.
Digest: This trial failure may influence adoption patterns of embolic protection devices in TAVR and could impact regulatory pathways and reimbursement decisions for this device class.

TAVR benefits high-risk patients with moderate aortic stenosis
The PROGRESS trial demonstrated that TAVR with a balloon-expandable valve reduced the risk of death or heart failure events at 2 years compared with clinical surveillance in high-risk patients with moderate aortic stenosis and at-risk features. The primary safety outcome at 30 days occurred in 5.9% of patients, meeting the performance goal, while the primary effectiveness outcome at 2 years occurred in 16.7% of the TAVR group.
Digest: This randomized trial challenges current practice by demonstrating clinical benefit of early intervention in moderate aortic stenosis, potentially expanding TAVR indications beyond severe disease in selected high-risk patients.
Abbott Announces 30-day Clinical Trial Results for Coronary Intravascular Lithotripsy System
Abbott announced 30-day results from a clinical trial evaluating its coronary intravascular lithotripsy (IVL) system for treating calcified coronary artery lesions. The trial assessed safety and performance of the device in modifying severely calcified coronary lesions prior to stenting.
Digest: This represents Abbott's entry into the coronary IVL space, a market currently dominated by Shockwave Medical, and could expand treatment options for complex calcified coronary disease that structural heart teams encounter in TAVR and other transcatheter procedures.
TAVR linked to key benefits for select heart patients with moderate aortic stenosis
Transcatheter aortic valve replacement (TAVR) demonstrated clinical benefits in selected patients with moderate aortic stenosis, expanding potential indications beyond current severe stenosis criteria. The findings suggest TAVR may benefit a broader patient population than currently approved.
Digest: This represents a potential paradigm shift in TAVR eligibility that could significantly expand the treatable patient population and market, though awaits definitive trial data and regulatory consideration.
EARLY TAVR update: New data highlight economic benefits of treating asymptomatic aortic stenosis
New health economic data from the EARLY TAVR trial demonstrate cost-effectiveness of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The analysis supports earlier intervention before symptom onset in appropriately selected patients.
Digest: Cost-effectiveness data may influence payer coverage decisions and clinical adoption of TAVR in asymptomatic patients, a potentially large untreated population that could significantly expand the structural heart market.
First patients treated for TRIUMPH trial focused on new TTVR tech
The TRIUMPH trial has enrolled and treated its first patients to evaluate a new transcatheter tricuspid valve replacement (TTVR) technology. This first-in-human milestone marks the initiation of clinical investigation for this novel device platform.
Digest: TTVR remains an emerging and technically challenging space with limited approved devices, making early-stage clinical trial data critical for assessing new competitive technologies entering the tricuspid intervention market.
Abbott now enrolling patients for new research on Cephea mitral valve replacement device
Abbott has initiated patient enrollment for a new clinical study evaluating the Cephea transcatheter mitral valve replacement system. The trial represents continued development of Abbott's TMVR platform for treating mitral valve disease.
Digest: This enrollment milestone advances Abbott's competitive position in the developing TMVR market, where multiple platforms are vying for clinical validation and eventual regulatory approval.

FDA approves new tricuspid valve repair system
The FDA approved Edwards Lifesciences' PASCAL Precision system for transcatheter tricuspid valve repair in patients with symptomatic severe tricuspid regurgitation at elevated surgical risk despite optimal medical therapy. Approval was based on 1-year results from the CLASP TR trial of 65 patients demonstrating significant improvement in tricuspid regurgitation severity with durable outcomes.
Digest: This approval expands the transcatheter treatment options for severe tricuspid regurgitation in the US market, addressing a historically underserved patient population with limited therapeutic alternatives.
TAVR linked to lower risk of in-hospital mortality than SAVR
A study found that transcatheter aortic valve replacement (TAVR) was associated with lower in-hospital mortality compared to surgical aortic valve replacement (SAVR). The analysis suggests improved short-term safety outcomes with the transcatheter approach.
Digest: This mortality data may influence treatment selection algorithms and further support TAVR expansion across risk categories, impacting procedural volumes and reimbursement strategies.

Study: Heart Valve Replacement Has Different Risks for Women vs. Men
A study of 1,114 TAVR patients at Karl Landsteiner University identified sex-specific differences in outcomes related to pacemaker implantation following the procedure. Women showed increased vulnerability immediately after new pacemaker implantation post-TAVR, while pre-existing pacemakers in men were associated with long-term risk.
Digest: These findings suggest that sex-specific risk stratification for conduction abnormalities and pacemaker need should be incorporated into pre-procedural TAVR assessment and post-procedural management, particularly as TAVR expands to younger, lower-risk populations.

NIH Awards Grant to Help Improve Mitral Valve Surgery Decisions
Mount Sinai researchers received a $3.6 million, four-year NIH grant to develop EVOLVE-MR, a project linking randomized trial data with Medicare records to extend mitral valve surgery evidence to real-world populations. The study will use machine learning and causal inference methods to determine whether clinical trial benefits persist in broader, more diverse patient groups over longer follow-up periods.
Digest: This research addresses the critical gap between clinical trial populations and real-world mitral regurgitation patients, potentially enabling more individualized surgical decision-making for the 13 million U.S. adults with valvular heart disease.
Late-breaking clinical trials announced for TCT 2026 in San Diego
TCT 2026 conference organizers have announced the slate of late-breaking clinical trials to be presented in San Diego. The announcement indicates which studies will be featured, though specific trial names and data are not yet disclosed.
Digest: Late-breaking trial announcements at TCT typically include pivotal structural heart studies that influence clinical practice and regulatory decisions in the interventional cardiology field.
Heart failure before and after TAVR: New data point to ongoing concerns
New data reveal ongoing concerns about heart failure occurrence both before and after transcatheter aortic valve replacement procedures. The findings highlight persistent clinical challenges in managing heart failure in TAVR patient populations.
Digest: Heart failure remains a critical complication affecting TAVR outcomes and patient selection, with implications for pre-procedural optimization and post-procedural surveillance strategies.
‘This could be transformative’: Surgeon performs first US implant of heart valve still under FDA review
A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.
Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

Transcatheter repair wins for severe tricuspid regurgitation
The TRIC-I-HF trial demonstrated that transcatheter tricuspid valve repair plus optimal medical therapy was superior to medical therapy alone in patients with symptomatic severe tricuspid regurgitation and heart failure. The intervention reduced all-cause death and HF hospitalization with benefits emerging early and sustained to 3 years, along with meaningful quality of life improvements.
Digest: This represents the first time transcatheter tricuspid repair has shown significant reductions in hard clinical endpoints (mortality and HF hospitalization), not just quality of life, potentially establishing a new standard of care for severe tricuspid regurgitation patients.

Milvexian did not reduce ischemic risk in recent ACS
The phase 3 LIBREXIA trial evaluating milvexian, an oral factor XIa inhibitor, was halted early for futility in patients with recent acute coronary syndrome at high risk for recurrent ischemic events. Milvexian added to antiplatelet therapy did not reduce cardiovascular death, MI, or ischemic stroke compared with placebo, though no excess bleeding risk was observed.
Digest: This trial demonstrates that factor XIa inhibition does not provide additional ischemic protection in ACS patients on antiplatelet therapy, though the lack of bleeding signal may inform ongoing anticoagulation strategies in structural heart interventions where thrombotic and hemorrhagic balance is critical.
No significant sex-based differences in timing of care for M-TEER patients
An analysis found no significant sex-based differences in timing of care for patients undergoing mitral transcatheter edge-to-edge repair (M-TEER). The study suggests that male and female patients receive similarly timed treatment access and procedural care.
Digest: Demonstrates equity in care delivery for M-TEER procedures across sexes, addressing ongoing concerns about potential gender disparities in access to advanced structural heart interventions.
TAVR is safe for patients with large aortic annuli—heart failure remains a concern
A study demonstrates that transcatheter aortic valve replacement is safe in patients with large aortic annuli. Heart failure complications remain an area of concern in this patient population.
Digest: Expands evidence for TAVR applicability in anatomically challenging cases with larger annular dimensions, though persistent heart failure risk may influence device selection and patient management strategies.
New PARTNER 3 update links TAVR to early benefits over SAVR
New data from the PARTNER 3 trial demonstrate early clinical benefits of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in low-risk patients. The updated analysis reinforces TAVR's favorable early outcomes in this patient population.
Digest: These findings support expanding TAVR utilization in low-risk surgical candidates and may influence treatment algorithms and guideline recommendations for aortic stenosis management.

Clinical Study to Look at Real-World Use of Transcatheter Edge-to-Edge Repair System for Leaky Tricuspid Heart Valve
Abbott has initiated the Treat TR study, a post-market study enrolling approximately 1,000 patients across up to 100 sites in the U.S., Canada, and Europe to evaluate the safety and performance of the TriClip transcatheter edge-to-edge repair system for tricuspid regurgitation in real-world settings. Patients will be followed for five years, with a sub-study examining the system's potential to reverse cardiac remodeling.
Digest: This large-scale real-world evidence study will provide critical post-market performance data for TriClip TEER, informing adoption decisions and potentially expanding treatment paradigms for TR in clinical practice.
EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis
New follow-up data from the EARLY TAVR trial demonstrate continued clinical benefits of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The updated results reinforce the safety and efficacy of early intervention before symptom onset in this patient population.
Digest: These findings support expanding TAVR utilization to asymptomatic patients with severe AS, potentially shifting treatment paradigms and increasing the addressable patient population for structural heart programs.
TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data
Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.
Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

Self-expanding TAVR valve helps patients with small aortic annuli
The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).
Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.
SAPT after TAVR linked to key benefits over DAPT, new data confirm
New data confirm that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement demonstrates key clinical benefits compared to dual antiplatelet therapy (DAPT). The findings support a streamlined antithrombotic strategy that may reduce bleeding complications while maintaining efficacy.
Digest: This evidence could influence anticoagulation management protocols post-TAVR, potentially reducing bleeding risk and healthcare costs while simplifying patient management for the growing TAVR population.
Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis
A new meta-analysis demonstrates that conduction system pacing following transcatheter aortic valve replacement is associated with improved clinical outcomes compared to conventional right ventricular pacing. The analysis suggests conduction system pacing may be a preferred pacing strategy for TAVR patients requiring permanent pacemaker implantation.
Digest: This finding could influence pacing strategy selection in the significant proportion of TAVR patients who develop conduction abnormalities requiring permanent pacemaker, potentially reducing long-term morbidity associated with right ventricular pacing.
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Regurgitation: the PRAISE-MR Randomized Trial
The PRAISE-MR randomized trial evaluated angiotensin receptor neprilysin inhibitor (ARNI) therapy in patients with heart failure with preserved ejection fraction (HFpEF) and secondary mitral regurgitation. The study assessed whether ARNI treatment could reduce mitral regurgitation severity and improve clinical outcomes in this patient population.
Digest: This trial addresses whether medical therapy with ARNI can reduce secondary MR in HFpEF patients, potentially identifying responders who may avoid transcatheter mitral intervention versus non-responders who require TMVR.
SMART update: Self-expanding TAVR valves still linked to superior durability after 3 years
Three-year follow-up data from the SMART trial continues to demonstrate superior structural valve deterioration outcomes for self-expanding TAVR valves compared to balloon-expandable systems. The durability advantage of self-expanding valves persisted at the 3-year time point.
Digest: This extends evidence supporting differential long-term durability between TAVR platform designs, which is critical for valve selection decisions particularly in younger, lower-risk patients where long-term performance drives clinical and economic outcomes.
Stroke prevention devices for TAVR fail to make an impact
Cerebral embolic protection devices designed to prevent stroke during transcatheter aortic valve replacement procedures have failed to demonstrate clinical benefit in trials and real-world use. Despite mechanistic rationale and debris capture evidence, these devices have not shown reduction in stroke rates or neurocognitive outcomes, limiting their adoption in routine TAVR practice.
Digest: The lack of clinical efficacy for stroke prevention devices leaves periprocedural stroke as an unresolved complication of TAVR, affecting patient counseling, procedural risk assessment, and development priorities for next-generation protective technologies.
Women live longer after TAVR than men
A study demonstrates that women undergoing transcatheter aortic valve replacement (TAVR) experience longer survival compared to men following the procedure. This sex-based difference in post-TAVR mortality represents an important outcome disparity in structural heart interventions.
Digest: Understanding sex-specific outcomes after TAVR is critical for risk stratification, patient selection, and informed consent discussions, particularly as TAVR expands into lower-risk and younger patient populations.
Popular weight loss drug linked to key benefits for patients undergoing TAVR, PCI
A study found that GLP-1 receptor agonist weight loss medications were associated with clinical benefits in patients undergoing transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). Specific outcome data including mortality, cardiovascular events, or procedural success rates were not detailed in the provided excerpt.
Digest: GLP-1 agonist use may influence risk stratification and periprocedural optimization strategies for TAVR candidates, particularly in obese or diabetic populations.
When bioprosthetic mitral valves fail: Redo surgery bests transcatheter treatment after 5 years
A five-year comparative study found that redo surgical mitral valve replacement outperformed transcatheter valve-in-valve mitral replacement for failed bioprosthetic mitral valves. The superior long-term outcomes of redo surgery over the transcatheter approach challenge current treatment preferences for this patient population.
Digest: This data may influence decision-making between redo surgical MVR and transcatheter valve-in-valve procedures, particularly in patients with acceptable surgical risk and longer life expectancy.
Early SAVR in asymptomatic heart patients linked to long-term benefits
Early surgical aortic valve replacement (SAVR) in asymptomatic patients with aortic stenosis demonstrated long-term clinical benefits compared to conservative management. The study suggests intervention prior to symptom onset may improve outcomes in select patients with severe AS.
Digest: This challenges the traditional watchful waiting approach for asymptomatic severe AS and may influence guideline recommendations regarding timing of intervention in this patient population.

Highlighting Innovation at the University of Colorado Hospital Cardiology Program
University of Colorado Hospital's Heart and Vascular Center performs approximately 3,000 interventional and structural heart procedures annually, including complex PCI with hemodynamic support and transcatheter mitral valve repair. The program has participated in pivotal trials for structural heart devices and performs 25-50 chronic total occlusion procedures and 50 Impella-supported high-risk PCI cases per year.
Digest: This academic center's experience with MitraClip procedures, complex high-risk PCI, and participation in pivotal device trials provides insights into advanced structural heart program development and procedural volumes at high-performing institutions.